The Market for Implanted Pain Neuromodulation Systems: 2021-2026

This newly published market research report examines the market for implantable pain neuromodulation devices in the years subsequent to the coronavirus pandemic. The report covers the events and developments that will impact the implanted pain neuromodulation system marketplace in the years 2021 through 2026. These include the impact of the pandemic, the segmentation of neuromodulation therapies, consolidation and M&A activity within the space, and the role played by an influx of new implanting clinicians in the years ahead.

The report offers authoritative market forecasts for revenues and growth rates of SCS and PNS systems, both worldwide and within the U.S. We also include our estimates of worldwide market share for both SCS and PNS systems, and we discuss potential new entrants in the
industry.

The editors conducted more than three dozen interviews with implanting physicians in 2020, after the onset of the pandemic. In addition, we conducted confidential interviews with executives and former executives of several publicly traded and privately held neuromodulation firms. This authoritative and timely report includes valuable market intelligence on the neuromodulation industry such as:

• The segmentation and differentiation within the SCS and PNS industry
• Comprehensive profiles of the key public and private competitors in the space
• The key indications identified by implanters as best suited for SCS or PNS therapies
• Reimbursement update for SCS and PNS systems
• Likely new entrants in the pain neuromodulation space